Revolution Medicines, Inc. (RVMD)Healthcare | Biotechnology | Redwood City, United States | NasdaqGS
190.87 USD
-3.08
(-1.589%) ⇩
(Oct. 13, 2026, 12:40 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:28 a.m. EDT
Revolution Medicines presents a high-stakes biotech opportunity where the balance sheet is a fortress but the earnings engine is currently stalled. The company holds substantial net cash and a robust current ratio, providing ample runway despite rapid cash burn, which supports a solid long-term outlook despite the lack of profitability. However, the stock is currently trading below its fifty-day moving average, indicating a short-term technical pullback after a massive rally from the 2025 anchor levels. While analysts remain optimistic with a strong buy consensus and a target price implying significant upside, the absence of earnings makes valuation difficult. Options flow confirms this tension, with traders buying calls targeting the $200 to $230 zone while maintaining protective put positions. For investors, this is a speculative play on future clinical milestones rather than a value investment, requiring tolerance for extreme volatility and the possibility of total capital loss if development stalls. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.043079 |
| AutoARIMA | 0.063538 |
| MSTL | 0.070432 |
| AutoETS | 0.071058 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 48% |
| H-stat | 0.84 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.375 |
| Excess Kurtosis | -0.84 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 45.678 |
| Market Cap | 40,909,852,672 |
| Forward P/E | -32.74 |
| Beta | 1.40 |
| Website | https://www.revmed.com |
As of Oct. 10, 2026, 9:28 a.m. EDT: Speculators are positioning for elevated volatility with implied volatility ranging between 50% and 65%. Call open interest clusters heavily at the $200 to $230 strike range for October through December 2026, indicating a bullish bias for a move above current levels. Put open interest is concentrated at lower strikes around $180 to $200, suggesting traders are hedging downside risk rather than betting purely on a crash.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.083158 |
| Address1 | 700 Saginaw Drive |
| All Time High | 224.31 |
| All Time Low | 14.08 |
| Ask | 208.54 |
| Ask Size | 2 |
| Audit Risk | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 2,021,610 |
| Average Daily Volume3 Month | 1,945,492 |
| Average Volume | 1,945,492 |
| Average Volume10Days | 2,021,610 |
| Beta | 1.401 |
| Bid | 176.46 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 12.165 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 190.8675 |
| Current Ratio | 11.378 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 193.61 |
| Day Low | 190.12 |
| Debt To Equity | 45.678 |
| Display Name | Revolution Medicines |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,960,000 |
| Earnings Call Timestamp Start | 1,785,960,000 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -1,618,188,032 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -23.992 |
| Enterprise Value | 38,823,051,264 |
| Eps Current Year | -9.60236 |
| Eps Forward | -5.83046 |
| Eps Trailing Twelve Months | -8.87 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 203.5571 |
| Fifty Day Average Change | -12.689606 |
| Fifty Day Average Change Percent | -0.062339295 |
| Fifty Two Week Change Percent | 308.3158 |
| Fifty Two Week High | 224.31 |
| Fifty Two Week High Change | -33.442505 |
| Fifty Two Week High Change Percent | -0.14909057 |
| Fifty Two Week Low | 47.45 |
| Fifty Two Week Low Change | 143.4175 |
| Fifty Two Week Low Change Percent | 3.0224972 |
| Fifty Two Week Range | 47.45 - 224.31 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,581,604,200,000 |
| Float Shares | 184,607,957 |
| Forward Eps | -5.83046 |
| Forward P E | -32.736267 |
| Free Cashflow | -711,607,360 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 883 |
| Fullday Change | -3.0825043 |
| Fullday Change Percent | -1.5893294 |
| Fullday Price | 190.8675 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -1,296,338,048 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.018509999 |
| Held Percent Institutions | 1.0126799 |
| Implied Shares Outstanding | 214,336,418 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. |
| Long Name | Revolution Medicines, Inc. |
| Market | us_market |
| Market Cap | 40,909,852,672 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_283775412 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -1,768,285,056 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 40,880,385,005 |
| Number Of Analyst Opinions | 23 |
| Open | 191.57 |
| Operating Cashflow | -1,223,032,960 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Phone | 650 481 6801 |
| Previous Close | 193.95 |
| Price Eps Current Year | -19.877144 |
| Price Hint | 2 |
| Price To Book | 15.689888 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.122 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.29167 |
| Region | US |
| Regular Market Change | -3.0825043 |
| Regular Market Change Percent | -1.5893294 |
| Regular Market Day High | 193.61 |
| Regular Market Day Low | 190.12 |
| Regular Market Day Range | 190.12 - 193.61 |
| Regular Market Open | 191.57 |
| Regular Market Previous Close | 193.95 |
| Regular Market Price | 190.8675 |
| Regular Market Time | 1,791,909,615 |
| Regular Market Volume | 820,271 |
| Return On Assets | -0.30122 |
| Return On Equity | -0.79089 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 214,336,418 |
| Shares Percent Shares Out | 0.0556 |
| Shares Short | 11,925,485 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,727,133 |
| Short Name | Revolution Medicines, Inc. |
| Short Percent Of Float | 0.0588 |
| Short Ratio | 5.9 |
| Source Interval | 15 |
| State | CA |
| Symbol | RVMD |
| Target High Price | 320.0 |
| Target Low Price | 179.0 |
| Target Mean Price | 259.1413 |
| Target Median Price | 260.0 |
| Total Cash | 3,937,968,896 |
| Total Cash Per Share | 18.373 |
| Total Debt | 1,190,470,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -8.87 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 149.48172 |
| Two Hundred Day Average Change | 41.385773 |
| Two Hundred Day Average Change Percent | 0.27686176 |
| Type Disp | Equity |
| Volume | 820,271 |
| Website | https://www.revmed.com |
| Zip | 94,063 |